Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2023 | May 11, 2023 | |
Document Information Line Items | ||
Entity Registrant Name | REFLECT SCIENTIFIC, INC. | |
Document Type | 10-Q | |
Current Fiscal Year End Date | --12-31 | |
Entity Common Stock, Shares Outstanding | 85,214,086 | |
Amendment Flag | false | |
Entity Central Index Key | 0001103090 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Document Period End Date | Mar. 31, 2023 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 000-31377 | |
Entity Incorporation, State or Country Code | UT | |
Entity Tax Identification Number | 87-0642556 | |
Entity Address, Address Line One | 1266 South 1380 West | |
Entity Address, City or Town | Orem | |
Entity Address, State or Province | UT | |
Entity Address, Postal Zip Code | 84058 | |
City Area Code | (801) | |
Local Phone Number | 226-4100 | |
Entity Interactive Data Current | Yes | |
Title of 12(b) Security | None |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Current Assets | ||
Cash and cash equivalents | $ 1,199,069 | $ 1,381,927 |
Accounts receivable, net | 108,368 | 129,329 |
Inventories, net | 850,620 | 797,352 |
Prepaid expenses and other current assets | 6,000 | 20,221 |
Total Current Assets | 2,164,057 | 2,328,829 |
Operating lease right-of-use assets | 39,736 | 54,265 |
Goodwill | 60,000 | 60,000 |
Other long-term assets | 3,100 | 3,100 |
TOTAL ASSETS | 2,266,893 | 2,446,194 |
Current Liabilities | ||
Accounts payable and accrued expenses | 68,196 | 78,969 |
Customer deposits | 810 | 13,230 |
Current portion of operating lease liabilities | 42,249 | 57,393 |
Total Current Liabilities | 111,255 | 149,592 |
TOTAL LIABILITIES | 111,255 | 149,592 |
Stockholders' Equity | ||
Preferred Stock, $0.01 par value, 5,000,000 shares authorized; none issued and outstanding as of March 31, 2023 and December 31, 2022 | ||
Common shares, $0.01 par value, 100,000,000 shares authorized; 85,214,086 shares issued and outstanding as of March 31, 2023 and December 31, 2022 | 852,140 | 852,140 |
Additional paid-in capital | 20,259,056 | 20,252,181 |
Accumulated deficit | (18,955,558) | (18,807,719) |
TOTAL STOCKHOLDERS’ EQUITY | 2,155,638 | 2,296,602 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 2,266,893 | $ 2,446,194 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares | Mar. 31, 2023 | Dec. 31, 2022 |
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | ||
Preferred stock, shares outstanding | ||
Common stock, par value (in Dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 85,214,086 | 85,214,086 |
Common stock, shares outstanding | 85,214,086 | 85,214,086 |
Condensed Consolidated Statemen
Condensed Consolidated Statements Of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Income Statement [Abstract] | ||
Revenues | $ 241,127 | $ 753,576 |
Cost of goods sold | 113,633 | 234,289 |
Gross profit | 127,494 | 519,287 |
Operating Expenses | ||
Salaries and wages | 162,275 | 170,279 |
General and administrative | 106,992 | 117,178 |
Research and development | 6,066 | 25,325 |
Total Operating Expenses | 275,333 | 312,782 |
INCOME (LOSS) FROM OPERATIONS | (147,839) | 206,505 |
NET INCOME (LOSS) BEFORE INCOME TAXES | (147,839) | 206,505 |
INCOME TAX BENEFIT (EXPENSE) | ||
NET INCOME (LOSS) | $ (147,839) | $ 206,505 |
Earnings (loss) per common share | ||
Basic (in Dollars per share) | $ 0 | $ 0 |
Diluted (in Dollars per share) | $ 0 | $ 0 |
Weighted average shares outstanding | ||
Basic (in Shares) | 85,214,086 | 84,989,086 |
Diluted (in Shares) | 85,214,086 | 85,739,086 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) - USD ($) | Common Shares | Additional Paid-In Capital | Accumulated Deficit | Total |
Balance at Dec. 31, 2021 | $ 849,890 | $ 20,226,931 | $ (18,897,115) | $ 2,179,706 |
Balance (in Shares) at Dec. 31, 2021 | 84,989,086 | |||
Stock-based compensation | 12,844 | 12,844 | ||
Net income (loss) | 206,505 | 206,505 | ||
Balance at Mar. 31, 2022 | $ 849,890 | 20,239,775 | (18,690,610) | 2,399,055 |
Balance (in Shares) at Mar. 31, 2022 | 84,989,086 | |||
Balance at Dec. 31, 2022 | $ 852,140 | 20,252,181 | (18,807,719) | 2,296,602 |
Balance (in Shares) at Dec. 31, 2022 | 85,214,086 | |||
Stock-based compensation | 6,875 | 6,875 | ||
Net income (loss) | (147,839) | (147,839) | ||
Balance at Mar. 31, 2023 | $ 852,140 | $ 20,259,056 | $ (18,955,558) | $ 2,155,638 |
Balance (in Shares) at Mar. 31, 2023 | 85,214,086 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cashflows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net income (loss) | $ (147,839) | $ 206,505 |
Adjustments to reconcile net income to net cash (used in) provided by operating activities: | ||
Stock-based compensation | 6,875 | 12,844 |
Amortization of right-of-use assets | 14,529 | 13,871 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 20,961 | (57,680) |
Inventories | (53,268) | (71,121) |
Prepaid expenses and other current assets | 14,221 | 27,796 |
Accounts payable and accrued expenses | (10,773) | 16,609 |
Customer deposits | (12,420) | (29,563) |
Operating lease liabilities | (15,144) | (13,652) |
Net cash (used in) provided by operating activities | (182,858) | 105,609 |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Net cash provided by investing activities | ||
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Net cash provided by financing activities | ||
NET CHANGE IN CASH AND CASH EQUIVALENTS | (182,858) | 105,609 |
CASH AND CASH EQUIVALENTS | ||
Beginning of the period | 1,381,927 | 1,473,924 |
End of the period | 1,199,069 | 1,579,533 |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||
Cash paid for interest | ||
Cash paid for income taxes |
Basis of Presentation
Basis of Presentation | 3 Months Ended |
Mar. 31, 2023 | |
Basis of Presentation [Abstract] | |
BASIS OF PRESENTATION | NOTE 1—BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements of Reflect Scientific, Inc. (the “Company,” “we,” “us,” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q of Regulation S-X. They do not include all information and footnotes required by GAAP for complete financial statements. The December 31, 2022 consolidated balance sheet data was derived from audited financial statements but do not include all disclosures required by GAAP. However, except as disclosed herein, there has been no material change in the information disclosed in the notes to the consolidated financial statements for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 31, 2023. The interim unaudited condensed consolidated financial statements should be read in conjunction with those consolidated financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial statements, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2023 are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. |
Recent Accounting Pronouncement
Recent Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2023 | |
Basis of Presentation [Abstract] | |
RECENT ACCOUNTING PRONOUNCEMENTS | NOTE 2—RECENT ACCOUNTING PRONOUNCEMENTS The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). The Company has evaluated all recent accounting pronouncements and determined that the adoption of pronouncements applicable to the Company has not had or is not expected to have a material impact on the Company's condensed consolidated financial statements. |
Disaggregation of Revenues
Disaggregation of Revenues | 3 Months Ended |
Mar. 31, 2023 | |
Disaggregation of Revenues Disclosure [Abstract] | |
DISAGGREGATION OF REVENUES | NOTE 3—DISAGGREGATION OF REVENUES Our revenue is disaggregated based on product category and geographical region. We recognize revenue from the sale of scientific equipment for the life sciences and manufacturing industries. Our products range from non-mechanical Cyrometrix freezers, chillers, and original equipment manufacturer (“OEM”) value-added products and components for the life sciences industry. The Company’s revenues for the three months ended March 31, 2023 and 2022 are disaggregated as follows: Three Months Ended March 31, 2023 United States International Total Revenues Freezers and chillers $ 45,250 $ - $ 45,250 OEM and other 127,880 67,997 195,877 Total Revenues $ 173,130 $ 67,997 $ 241,127 Three Months Ended March 31, 2022 United States International Total Revenues Freezers and chillers $ 348,458 $ 153,236 $ 501,694 OEM and other 172,443 79,439 251,882 Total Revenues $ 520,901 $ 232,675 $ 753,576 |
Inventories
Inventories | 3 Months Ended |
Mar. 31, 2023 | |
Inventories [Abstract] | |
INVENTORIES | NOTE 4—INVENTORIES Inventories at March 31, 2023 and December 31, 2022 consisted of the following: March 31, December 31, Finished goods $ 363,010 $ 376,334 Raw materials 593,654 527,062 Total inventories 956,664 903,396 Less reserve for obsolescence (106,044 ) (106,044 ) Total inventories, net $ 850,620 $ 797,352 Inventory balances are composed of finished goods. Raw materials and work in process inventory are immaterial to the condensed consolidated financial statements. |
Leases
Leases | 3 Months Ended |
Mar. 31, 2023 | |
Leases [Abstract] | |
LEASES | NOTE 5—LEASES The following was included in our condensed consolidated balance sheet at March 31, 2023 and December 31, 2022: March 31, December 31, Operating lease right-of-use assets $ 39,736 $ 54,265 Lease liabilities, current portion 42,249 57,393 Lease liabilities, long-term - - Total operating lease liabilities $ 42,249 $ 57,393 Weighted-average remaining lease term (months) 8 11 Weighted average discount rate 5.25% 5.25% Total lease expense for the three months ended March 31, 2023 and 2022 is as follows: Three Months Ended March 31, 2023 2022 Operating lease expense $ 15,216 $ 15,216 Variable lease expense 4,437 2,393 Total lease expense $ 19,653 $ 17,609 As of March 31, 2023, maturities of operating lease liabilities were as follows: Year Ending December 31, Amount 2023 – remaining $ 43,089 Less: imputed interest (840 ) Total operating lease liabilities $ 42,249 |
Stockholders' Equity
Stockholders' Equity | 3 Months Ended |
Mar. 31, 2023 | |
Stockholders' Equity Note [Abstract] | |
STOCKHOLDERS’ EQUITY | NOTE 6—STOCKHOLDERS’ EQUITY Common Stock As of March 31, 2023, the Company was authorized to issue 100,000,000 common shares. As of March 31, 2023 and December 31, 2022, the Company had 85,214,086 common shares issued and outstanding. Restricted Stock Awards Below is a table summarizing the changes in restricted stock awards outstanding during the three months ended March 31, 2023: Restricted Stock Awards Weighted- Outstanding at December 31, 2022 450,000 $ 0.11 Granted - - Vested - - Forfeited - - Outstanding at March 31, 2023 450,000 $ 0.11 Stock-based compensation expense of $6,875 and $12,844 was recorded during the three months ended March 31, 2023 and 2022, respectively. As of March 31, 2023, the remaining unrecognized stock-based compensation expense related to non-vested restricted stock awards is $48,125 and is expected to be recognized over 1.75 years. |
Earnings (Loss) Per Share
Earnings (Loss) Per Share | 3 Months Ended |
Mar. 31, 2023 | |
Earnings (Loss) Per Share [Abstract] | |
EARNINGS (LOSS) PER SHARE | NOTE 7—EARNINGS (LOSS) PER SHARE The computation of weighted average shares outstanding and the basic and diluted earnings per share for the three months ended March 31, 2023 and 2022 consisted of the following: Three Months Ended March 31, 2023 2022 Net income (loss) $ (147,839 ) $ 206,505 Weighted average shares outstanding 85,214,086 84,989,086 Basic earnings (loss) per share $ (0.00 ) $ 0.00 Weighted average shares outstanding 85,214,086 84,989,086 Effect on dilutive stock awards - 750,000 Total potential shares outstanding 85,214,086 85,739,086 Diluted earnings (loss) per share $ (0.00 ) $ 0.00 For the three months ended March 31, 2023,there were 450,000 common share equivalents excluded from the diluted earnings per share calculation as their effect is anti-dilutive. |
Disaggregation of Revenues (Tab
Disaggregation of Revenues (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Disaggregation of Revenues [Abstract] | |
Schedule of revenues | Three Months Ended March 31, 2023 United States International Total Revenues Freezers and chillers $ 45,250 $ - $ 45,250 OEM and other 127,880 67,997 195,877 Total Revenues $ 173,130 $ 67,997 $ 241,127 Three Months Ended March 31, 2022 United States International Total Revenues Freezers and chillers $ 348,458 $ 153,236 $ 501,694 OEM and other 172,443 79,439 251,882 Total Revenues $ 520,901 $ 232,675 $ 753,576 |
Inventories (Tables)
Inventories (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Inventories [Abstract] | |
Schedule of inventories | March 31, December 31, Finished goods $ 363,010 $ 376,334 Raw materials 593,654 527,062 Total inventories 956,664 903,396 Less reserve for obsolescence (106,044 ) (106,044 ) Total inventories, net $ 850,620 $ 797,352 |
Leases (Tables)
Leases (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Leases [Abstract] | |
Schedule of consolidated balance sheet | March 31, December 31, Operating lease right-of-use assets $ 39,736 $ 54,265 Lease liabilities, current portion 42,249 57,393 Lease liabilities, long-term - - Total operating lease liabilities $ 42,249 $ 57,393 Weighted-average remaining lease term (months) 8 11 Weighted average discount rate 5.25% 5.25% |
Schedule of lease expense | Three Months Ended March 31, 2023 2022 Operating lease expense $ 15,216 $ 15,216 Variable lease expense 4,437 2,393 Total lease expense $ 19,653 $ 17,609 |
Schedule of maturities of operating lease liabilities | Year Ending December 31, Amount 2023 – remaining $ 43,089 Less: imputed interest (840 ) Total operating lease liabilities $ 42,249 |
Stockholders' Equity (Tables)
Stockholders' Equity (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Stockholders' Equity Note [Abstract] | |
Schedule of changes in restricted stock awards outstanding | Restricted Stock Awards Weighted- Outstanding at December 31, 2022 450,000 $ 0.11 Granted - - Vested - - Forfeited - - Outstanding at March 31, 2023 450,000 $ 0.11 |
Earnings (Loss) Per Share (Tabl
Earnings (Loss) Per Share (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Earnings (Loss) Per Share [Abstract] | |
Schedule of weighted average shares outstanding and the basic and diluted earnings per share | Three Months Ended March 31, 2023 2022 Net income (loss) $ (147,839 ) $ 206,505 Weighted average shares outstanding 85,214,086 84,989,086 Basic earnings (loss) per share $ (0.00 ) $ 0.00 Weighted average shares outstanding 85,214,086 84,989,086 Effect on dilutive stock awards - 750,000 Total potential shares outstanding 85,214,086 85,739,086 Diluted earnings (loss) per share $ (0.00 ) $ 0.00 |
Disaggregation of Revenues (Det
Disaggregation of Revenues (Details) - Schedule of revenues - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Revenues | ||
Freezers and chillers | $ 45,250 | $ 501,694 |
OEM and other | 195,877 | 251,882 |
Total Revenues | 241,127 | 753,576 |
United States [Member] | ||
Revenues | ||
Freezers and chillers | 45,250 | 348,458 |
OEM and other | 127,880 | 172,443 |
Total Revenues | 173,130 | 520,901 |
International [Member] | ||
Revenues | ||
Freezers and chillers | 153,236 | |
OEM and other | 67,997 | 79,439 |
Total Revenues | $ 67,997 | $ 232,675 |
Inventories (Details) - Schedul
Inventories (Details) - Schedule of inventories - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Schedule of inventories [Abstract] | ||
Finished goods | $ 363,010 | $ 376,334 |
Raw materials | 593,654 | 527,062 |
Total inventories | 956,664 | 903,396 |
Less reserve for obsolescence | (106,044) | (106,044) |
Total inventories, net | $ 850,620 | $ 797,352 |
Leases (Details) - Schedule of
Leases (Details) - Schedule of consolidated balance sheet - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Schedule of Condensed Consolidated Balance Sheet [Abstract] | ||
Operating lease right-of-use assets | $ 39,736 | $ 54,265 |
Lease liabilities, current portion | 42,249 | 57,393 |
Lease liabilities, long-term | ||
Total operating lease liabilities | $ 42,249 | $ 57,393 |
Weighted-average remaining lease term (months) | 8 months | 11 months |
Weighted average discount rate | 5.25% | 5.25% |
Leases (Details) - Schedule o_2
Leases (Details) - Schedule of lease expense - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Schedule of Lease Expense [Abstract] | ||
Operating lease expense | $ 15,216 | $ 15,216 |
Variable lease expense | 4,437 | 2,393 |
Total lease expense | $ 19,653 | $ 17,609 |
Leases (Details) - Schedule o_3
Leases (Details) - Schedule of maturities of operating lease liabilities - Operating Lease Liabilities [Member] | Mar. 31, 2023 USD ($) |
Schedule of Maturities of Operating Lease Liabilities [Abstract] | |
2023 – remaining | $ 43,089 |
Less: imputed interest | (840) |
Total operating lease liabilities | $ 42,249 |
Stockholders' Equity (Details)
Stockholders' Equity (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | |
Stockholders' Equity Note [Abstract] | |||
Common stock, shares authorized | 100,000,000 | 100,000,000 | |
Common stock, shares issued | 85,214,086 | 85,214,086 | |
Stock based compensation expense (in Dollars) | $ 6,875 | $ 12,844 | |
Non-vested restricted stock awards (in Dollars) | $ 48,125 | ||
Non vested restricted stock awards period | 1 year 9 months | ||
Common stock, shares outstanding | 85,214,086 | 85,214,086 |
Stockholders' Equity (Details)
Stockholders' Equity (Details) - Schedule of changes in restricted stock awards outstanding | 3 Months Ended |
Mar. 31, 2023 $ / shares shares | |
Schedule of Changes in Restricted Stock Awards Outstanding [Abstract] | |
Restricted Stock Awards Outstanding, Beginning | shares | 450,000 |
Weighted-Average Exercise Price Outstanding, Beginning | $ / shares | $ 0.11 |
Restricted Stock Awards Outstanding, Granted | shares | |
Weighted-Average Exercise Price Outstanding, Granted | $ / shares | |
Restricted Stock Awards, Vested | shares | |
Weighted-Average Exercise Price, Vested | $ / shares | |
Restricted Stock Awards, Forfeited | shares | |
Weighted-Average Exercise Price Outstanding, Forfeited | $ / shares | |
Restricted Stock Awards Outstanding, Ending | shares | 450,000 |
Weighted-Average Exercise Price Outstanding, Ending | $ / shares | $ 0.11 |
Earnings (Loss) Per Share (Deta
Earnings (Loss) Per Share (Details) | 3 Months Ended |
Mar. 31, 2023 shares | |
Earnings (Loss) Per Share [Abstract] | |
Common share equivalents | 450,000 |
Earnings (Loss) Per Share (De_2
Earnings (Loss) Per Share (Details) - Schedule of weighted average shares outstanding and the basic and diluted earnings per share - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Schedule of Weighted Average Shares Outstanding and the Basic and Diluted Earnings Per Share [Abstract] | ||
Net income (loss) (in Dollars) | $ (147,839) | $ 206,505 |
Weighted average shares outstanding | 85,214,086 | 84,989,086 |
Basic earnings (loss) per share (in Dollars per share) | $ 0 | $ 0 |
Weighted average shares outstanding | 85,214,086 | 84,989,086 |
Effect on dilutive stock awards (in Dollars) | $ 750,000 | |
Total potential shares outstanding | 85,214,086 | 85,739,086 |
Diluted earnings (loss) per share (in Dollars per share) | $ 0 | $ 0 |